Latest Insider Transactions at Eiger Bio Pharmaceuticals, Inc. (EIGR)
This section provides a real-time view of insider transactions for Eiger Bio Pharmaceuticals, Inc. (EIGR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Eiger BioPharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Eiger BioPharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 02
2023
|
Richard A Kayne |
BUY
Open market or private purchase
|
Indirect |
23,398
+0.43%
|
$0
$0.3 P/Share
|
|
Nov 01
2023
|
Richard A Kayne |
BUY
Open market or private purchase
|
Indirect |
100,000
+1.83%
|
$0
$0.28 P/Share
|
|
Oct 31
2023
|
Richard A Kayne |
BUY
Open market or private purchase
|
Indirect |
154,841
+0.97%
|
$0
$0.25 P/Share
|
|
Oct 31
2023
|
Leen Kawas |
BUY
Open market or private purchase
|
Indirect |
24,332
+0.28%
|
$0
$0.26 P/Share
|
|
Mar 17
2023
|
Eldon C. Mayer Iii Ex VP & Chief Commerc. Officer |
SELL
Open market or private sale
|
Direct |
4,395
-3.7%
|
$4,395
$1.07 P/Share
|
|
Jan 23
2023
|
Thomas John Dietz |
BUY
Open market or private purchase
|
Indirect |
50,000
+50.0%
|
$50,000
$1.43 P/Share
|
|
Dec 29
2022
|
Christine Murray |
SELL
Open market or private sale
|
Direct |
5,000
-31.25%
|
$5,000
$1.22 P/Share
|
|
Dec 22
2022
|
Jeffrey S Glenn |
BUY
Open market or private purchase
|
Direct |
100,000
+35.42%
|
$100,000
$1.28 P/Share
|
|
Dec 22
2022
|
Thomas John Dietz |
SELL
Open market or private sale
|
Direct |
22,500
-51.72%
|
$22,500
$1.17 P/Share
|
|
Aug 16
2022
|
David Apelian CEO |
SELL
Open market or private sale
|
Direct |
5,000
-31.25%
|
$45,000
$9.81 P/Share
|
|
Mar 14
2022
|
Eldon C. Mayer Iii Ex VP & Chief Commerc. Officer |
SELL
Open market or private sale
|
Direct |
1,657
-2.67%
|
$8,285
$5.6 P/Share
|
|
Mar 14
2022
|
Sriram Ryali Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,266
-5.17%
|
$11,330
$5.6 P/Share
|
|
Mar 11
2022
|
David Apelian CEO |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+27.27%
|
-
|
|
Mar 11
2022
|
Erik Atkisson GC & Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Mar 11
2022
|
David A Cory President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
47,000
+21.74%
|
-
|
|
Mar 11
2022
|
Thomas John Dietz |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+12.12%
|
-
|
|
Mar 11
2022
|
Evan Loh |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+30.0%
|
-
|
|
Mar 11
2022
|
Jeffrey S Glenn |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+6.79%
|
-
|
|
Mar 11
2022
|
Eldon C. Mayer Iii Ex VP & Chief Commerc. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+20.48%
|
-
|
|
Mar 11
2022
|
Christine Murray |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+27.27%
|
-
|
|
Mar 11
2022
|
Sriram Ryali Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+35.38%
|
-
|
|
Mar 11
2022
|
Kim Sablich |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Mar 11
2022
|
Amit Sachdev |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+27.27%
|
-
|
|
Jan 07
2022
|
Eldon C. Mayer Iii Ex VP & Chief Commerc. Officer |
SELL
Open market or private sale
|
Direct |
1,560
-3.27%
|
$6,240
$4.95 P/Share
|
|
Apr 09
2021
|
Thomas John Dietz |
BUY
Open market or private purchase
|
Direct |
2,500
+3.27%
|
$20,000
$8.49 P/Share
|
|
Mar 15
2021
|
Evan Loh |
SELL
Open market or private sale
|
Direct |
2,000
-20.0%
|
$20,000
$10.14 P/Share
|
|
Mar 12
2021
|
David Apelian CEO |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+33.33%
|
-
|
|
Mar 12
2021
|
David A Cory President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
47,000
+28.51%
|
-
|
|
Mar 12
2021
|
Thomas John Dietz |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+12.5%
|
-
|
|
Mar 12
2021
|
Jeffrey S Glenn |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+6.15%
|
-
|
|
Mar 12
2021
|
Evan Loh |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+33.33%
|
-
|
|
Mar 12
2021
|
Eldon C. Mayer Iii Ex VP & Chief Commerc. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,875
+19.94%
|
-
|
|
Mar 12
2021
|
Christine Murray |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+33.33%
|
-
|
|
Mar 12
2021
|
Stephana Eilene Patton Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,875
+39.82%
|
-
|
|
Mar 12
2021
|
Sriram Ryali Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+47.24%
|
-
|
|
Mar 12
2021
|
Amit Sachdev |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+33.33%
|
-
|
|
Mar 12
2021
|
James P Shaffer Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,875
+28.84%
|
-
|
|
Jan 08
2021
|
Eldon C. Mayer Iii Ex VP & Chief Commerc. Officer |
SELL
Open market or private sale
|
Direct |
1,690
-4.51%
|
$18,590
$11.68 P/Share
|